Sparx
Latest round
- Series B
Last raised
- Dec 2021
Total raised
- $30M
Investors
- 3
About Sparx
Based in Yangzhou, China, and established in 2021, Sparx is a research-based development-stage biopharmaceutical company that provides immune anti-tumor therapy. The company is a subsidiary of Sparx Group, which incorporated by SparXBiopharmaceutical in US State, SparX Bioscience in England, SparX in Hong Kong, SparX in Jiangsu, and SparX in Shanghai. Sparx Group's R&D center in Chicago, established in 2018. And Sparx Group constructed in house CMP facilities in both Chicago and China to product clinical and commercial drug substance. The company plant in Jiangsu covers 120,000 square meters, including GMP of 40,000 square meters, providing all process of bio-pharmacy from R&D to manufacture. The company has built a sophisticated multi-specific antibody drug discovery platform and identified 6 IND-ready drug candidates. The SMARTOP™ and LEMMA™ technologies allow the expedite discovery of multi-functional biologics with favorable drug-like properties. An AI-based target identification algorithm feeds a constant stream of novel targets and target counterparts. Sparx has developed two mouse hybridoma protocols for quick and repetitive immunizations and built a phage display library of 1012 recombinant variants for human antibody discovery. The company develops specific antibodies and antibody drug conjugates, along with CAR-T cell therapy for broader applications of antibodies. In addition, Sparx has developed a new screening technology to expand the clinical applications of small molecular chemical entities as well as several tumor-targeting drug delivery technologies for both small molecule and macromolecule medicines. The company plans to build production facilities in Yangzhou, Jiangsu. Moreover, the company will promote process of R&D and manufacturing of 4 product lines.
Who invested in Sparx
3 investors across 1 round
See all investors in Sparx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Dec 31, 2021
Amount
$30M
Investors
Questions about Sparx
Who invested in Sparx?
Sparx has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sparx raised?
Sparx has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Sparx last raise money?
Sparx's most recent round on record is a Series B, in Dec 2021.
What does Sparx do?
Based in Yangzhou, China, and established in 2021, Sparx is a research-based development-stage biopharmaceutical company that provides immune anti-tumor therapy.
Where is Sparx headquartered?
Sparx is headquartered in Yangzhou, China.
Which VCs invest in companies like Sparx?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Sparx's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Sparx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.